METAVIA INC. Severance Costs
METAVIA INC. (MTVA) reported Severance Costs of $1.60 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2019-03-18
- METAVIA INC. severance costs for the quarter ending 2018-12-31 was $300.00K.
- METAVIA INC. severance costs for fiscal 2018 was $1.60M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2018-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $1.60M 10-K · filed 2019-03-18 | ||
| 2018-09-30 | $1.30M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $500.00K 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |